SCHEMBL20738544

SCHEMBL20738544

Cc1ccc(F)c([C@H](C)CO)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.38
CHRM1 P11229 2/20 0.38
ADRA1A P35348 2/20 0.38
TRPA1 O75762 1/20 0.38
SLC6A2 P23975 1/20 0.38
HTR2B P41595 1/20 0.38
PSEN1 P49768 1/20 0.36
PSEN2 P49810 1/20 0.36
APH1B Q8WW43 1/20 0.36
NCSTN Q92542 1/20 0.36
APH1A Q96BI3 1/20 0.36
PSENEN Q9NZ42 1/20 0.36
SRC P12931 1/20 0.35
POLB P06746 1/20 0.35
ADRA2A P08913 1/20 0.34
ADRA2B P18089 1/20 0.34
ADRA2C P18825 1/20 0.34
ACE2 Q9BYF1 2/20 0.33
MAPK1 P28482 1/20 0.33
MAP2K4 P45985 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18900319 0.82 TSHR (0.39) LMNACHRM1ADRA1ATRPA1SLC6A2
SCHEMBL18793777 0.79 ADRA2C (0.36) LMNACHRM1ADRA1ATRPA1SLC6A2
SCHEMBL21096068 0.79 PSEN1 (0.35) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL4597897 0.79 ADRA2C (0.36) LMNACHRM1ADRA1ATRPA1SLC6A2
SCHEMBL16954329 0.79 TRPA1 (0.33) LMNACHRM1ADRA1ATRPA1SLC6A2
SCHEMBL8251516 0.78 TRPA1 (0.42) LMNACHRM1ADRA1ATRPA1SLC6A2
SCHEMBL84060 0.77 TRPA1 (0.50) LMNACHRM1ADRA1ATRPA1SLC6A2
SCHEMBL29280989 0.77 LMNA (0.38) LMNACHRM1ADRA1ATRPA1SLC6A2
SCHEMBL9232866 0.77 SRC (0.36) LMNACHRM1ADRA1ATRPA1SLC6A2
SCHEMBL20738712 0.76 TRPA1 (0.45) LMNACHRM1ADRA1ATRPA1SLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230019032-A1 BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2023-01-19 US disclosed
US-11001575-B1 Benzolactam compounds as protein kinase inhibitors OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2021-05-11 US disclosed
US-10457669-B2 Benzolactam compounds as protein kinase inhibitors OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2019-10-29 US disclosed
US-20190047990-A1 BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2019-02-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230019032-A1 BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS MAPK1, ALK, MAP3K1 LMNA 816/4885CHRM1 227/4885ADRA1A 919/4885
US-20190047990-A1 BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS MAPK1, ALK, MAP3K1 LMNA 816/4885CHRM1 227/4885ADRA1A 919/4885
US-11001575-B1 Benzolactam compounds as protein kinase inhibitors MAPK1, ALK, MAP3K1 LMNA 600/4885CHRM1 209/4885ADRA1A 953/4885
US-10457669-B2 Benzolactam compounds as protein kinase inhibitors MAPK1, ALK, MAP3K1 LMNA 816/4885CHRM1 227/4885ADRA1A 919/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.